Liu Ling, Wang Siying, Chen Xuyu, Luo Qian, Wang Zhaoxia, Li Juan
Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China.
Aging (Albany NY). 2025 Feb 27;17(2):588-606. doi: 10.18632/aging.206210.
Human Methyltransferase-like 16(METTL16) is an independent N6-methyladenosine (m6A) methyltransferase. Previous studies have proven METTL16 been linked with some types of cancers. However, comparative studies of the relevance of METTL16 across diverse tumors remain sparse. We comprehensively investigated the effect of METTL16 expression on tumor prognosis across human malignancies by analyzing multiple cancer-related databases like Tumor Immune Estimation Resource (TIMER) and human protein atlas (HPA). Bioinformatics data indicated that METTL16 was overexpressed in most of these human malignancies and was significantly associated with the prognosis of patients with cancer, especially in colorectal cancer (CRC). Subsequently, experiments, the utility of METTL16 that downregulation of its expression could result in reduced proliferation and migration of CRC cells. Our findings reveal novel insights into METTL16 expression and its biological functions in diverse cancer types, indicating that METTL16 could serve as a prognostic biomarker and plays an important role in colorectal cancer.
人类甲基转移酶样蛋白16（METTL16）是一种独立的N6-甲基腺苷（m6A）甲基转移酶。先前的研究已证实METTL16与某些类型的癌症有关。然而，关于METTL16在不同肿瘤中相关性的比较研究仍然很少。我们通过分析多个癌症相关数据库，如肿瘤免疫评估资源（TIMER）和人类蛋白质图谱（HPA），全面研究了METTL16表达对人类恶性肿瘤患者肿瘤预后的影响。生物信息学数据表明，METTL16在大多数人类恶性肿瘤中过表达，并且与癌症患者的预后显著相关，尤其是在结直肠癌（CRC）中。随后，实验表明，下调METTL16的表达可导致CRC细胞的增殖和迁移减少。我们的研究结果揭示了METTL16在不同癌症类型中的表达及其生物学功能的新见解，表明METTL16可作为一种预后生物标志物，并在结直肠癌中发挥重要作用。
